Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B−/− (Wilson disease) mice

James Hamilton, Lahari Koganti, Abigael Muchenditsi, Venkata S. Pendyala, David Huso, Joseph Hankin, Robert C. Murphy, Dominik Huster, Uta Merle, Christopher Mangels, Nan Yang, James John Potter, Esteban Mezey, Svetlana Lutsenko

Research output: Contribution to journalArticle

Abstract

Wilson disease (WD) is a hepatoneurological disorder caused by mutations in the copper-transporter, ATP7B. Copper accumulation in the liver is a hallmark of WD. Current therapy is based on copper chelation, which decreases the manifestations of liver disease, but often worsens neurological symptoms. We demonstrate that in Atp7b−/− mice, an animal model of WD, liver function can be significantly improved without copper chelation. Analysis of transcriptional and metabolic changes in samples from WD patients and Atp7b−/− mice identified dysregulation of nuclear receptors (NRs), especially the liver X receptor (LXR)/retinoid X receptor heterodimer, as an important event in WD pathogenesis. Treating Atp7b−/− mice with the LXR agonist, T0901317, ameliorated disease manifestations despite significant copper overload. Genetic markers of liver fibrosis and inflammatory cytokines were significantly decreased, lipid profiles normalized, and liver function and histology were improved. Conclusions: The results demonstrate the major role of an altered NR function in the pathogenesis of WD and suggest that modulation of NR activity should be explored as a supplementary approach to improving liver function in WD. (Hepatology 2016;63:1828-1841).

Original languageEnglish (US)
Pages (from-to)1828-1841
Number of pages14
JournalHepatology
Volume63
Issue number6
DOIs
StatePublished - 2016

Fingerprint

Retinoid X Receptors
Hepatolenticular Degeneration
Liver Diseases
Copper
Cytoplasmic and Nuclear Receptors
Liver
Gastroenterology
Liver X Receptors
Genetic Markers
Liver Cirrhosis
Histology
Animal Models
Cytokines
Lipids
Mutation

ASJC Scopus subject areas

  • Hepatology

Cite this

Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B−/− (Wilson disease) mice. / Hamilton, James; Koganti, Lahari; Muchenditsi, Abigael; Pendyala, Venkata S.; Huso, David; Hankin, Joseph; Murphy, Robert C.; Huster, Dominik; Merle, Uta; Mangels, Christopher; Yang, Nan; Potter, James John; Mezey, Esteban; Lutsenko, Svetlana.

In: Hepatology, Vol. 63, No. 6, 2016, p. 1828-1841.

Research output: Contribution to journalArticle

Hamilton, J, Koganti, L, Muchenditsi, A, Pendyala, VS, Huso, D, Hankin, J, Murphy, RC, Huster, D, Merle, U, Mangels, C, Yang, N, Potter, JJ, Mezey, E & Lutsenko, S 2016, 'Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B−/− (Wilson disease) mice', Hepatology, vol. 63, no. 6, pp. 1828-1841. https://doi.org/10.1002/hep.28406
Hamilton, James ; Koganti, Lahari ; Muchenditsi, Abigael ; Pendyala, Venkata S. ; Huso, David ; Hankin, Joseph ; Murphy, Robert C. ; Huster, Dominik ; Merle, Uta ; Mangels, Christopher ; Yang, Nan ; Potter, James John ; Mezey, Esteban ; Lutsenko, Svetlana. / Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B−/− (Wilson disease) mice. In: Hepatology. 2016 ; Vol. 63, No. 6. pp. 1828-1841.
@article{941afefbbfe841589e88ed5e82c001d6,
title = "Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B−/− (Wilson disease) mice",
abstract = "Wilson disease (WD) is a hepatoneurological disorder caused by mutations in the copper-transporter, ATP7B. Copper accumulation in the liver is a hallmark of WD. Current therapy is based on copper chelation, which decreases the manifestations of liver disease, but often worsens neurological symptoms. We demonstrate that in Atp7b−/− mice, an animal model of WD, liver function can be significantly improved without copper chelation. Analysis of transcriptional and metabolic changes in samples from WD patients and Atp7b−/− mice identified dysregulation of nuclear receptors (NRs), especially the liver X receptor (LXR)/retinoid X receptor heterodimer, as an important event in WD pathogenesis. Treating Atp7b−/− mice with the LXR agonist, T0901317, ameliorated disease manifestations despite significant copper overload. Genetic markers of liver fibrosis and inflammatory cytokines were significantly decreased, lipid profiles normalized, and liver function and histology were improved. Conclusions: The results demonstrate the major role of an altered NR function in the pathogenesis of WD and suggest that modulation of NR activity should be explored as a supplementary approach to improving liver function in WD. (Hepatology 2016;63:1828-1841).",
author = "James Hamilton and Lahari Koganti and Abigael Muchenditsi and Pendyala, {Venkata S.} and David Huso and Joseph Hankin and Murphy, {Robert C.} and Dominik Huster and Uta Merle and Christopher Mangels and Nan Yang and Potter, {James John} and Esteban Mezey and Svetlana Lutsenko",
year = "2016",
doi = "10.1002/hep.28406",
language = "English (US)",
volume = "63",
pages = "1828--1841",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B−/− (Wilson disease) mice

AU - Hamilton, James

AU - Koganti, Lahari

AU - Muchenditsi, Abigael

AU - Pendyala, Venkata S.

AU - Huso, David

AU - Hankin, Joseph

AU - Murphy, Robert C.

AU - Huster, Dominik

AU - Merle, Uta

AU - Mangels, Christopher

AU - Yang, Nan

AU - Potter, James John

AU - Mezey, Esteban

AU - Lutsenko, Svetlana

PY - 2016

Y1 - 2016

N2 - Wilson disease (WD) is a hepatoneurological disorder caused by mutations in the copper-transporter, ATP7B. Copper accumulation in the liver is a hallmark of WD. Current therapy is based on copper chelation, which decreases the manifestations of liver disease, but often worsens neurological symptoms. We demonstrate that in Atp7b−/− mice, an animal model of WD, liver function can be significantly improved without copper chelation. Analysis of transcriptional and metabolic changes in samples from WD patients and Atp7b−/− mice identified dysregulation of nuclear receptors (NRs), especially the liver X receptor (LXR)/retinoid X receptor heterodimer, as an important event in WD pathogenesis. Treating Atp7b−/− mice with the LXR agonist, T0901317, ameliorated disease manifestations despite significant copper overload. Genetic markers of liver fibrosis and inflammatory cytokines were significantly decreased, lipid profiles normalized, and liver function and histology were improved. Conclusions: The results demonstrate the major role of an altered NR function in the pathogenesis of WD and suggest that modulation of NR activity should be explored as a supplementary approach to improving liver function in WD. (Hepatology 2016;63:1828-1841).

AB - Wilson disease (WD) is a hepatoneurological disorder caused by mutations in the copper-transporter, ATP7B. Copper accumulation in the liver is a hallmark of WD. Current therapy is based on copper chelation, which decreases the manifestations of liver disease, but often worsens neurological symptoms. We demonstrate that in Atp7b−/− mice, an animal model of WD, liver function can be significantly improved without copper chelation. Analysis of transcriptional and metabolic changes in samples from WD patients and Atp7b−/− mice identified dysregulation of nuclear receptors (NRs), especially the liver X receptor (LXR)/retinoid X receptor heterodimer, as an important event in WD pathogenesis. Treating Atp7b−/− mice with the LXR agonist, T0901317, ameliorated disease manifestations despite significant copper overload. Genetic markers of liver fibrosis and inflammatory cytokines were significantly decreased, lipid profiles normalized, and liver function and histology were improved. Conclusions: The results demonstrate the major role of an altered NR function in the pathogenesis of WD and suggest that modulation of NR activity should be explored as a supplementary approach to improving liver function in WD. (Hepatology 2016;63:1828-1841).

UR - http://www.scopus.com/inward/record.url?scp=84978193472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978193472&partnerID=8YFLogxK

U2 - 10.1002/hep.28406

DO - 10.1002/hep.28406

M3 - Article

VL - 63

SP - 1828

EP - 1841

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 6

ER -